Cargando…

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib

BACKGROUND: Trifluridine and tipiracil (FTD + TPI) and regorafenib (REG) are approved treatments for the treatment of refractory metastatic colorectal cancer (mCRC). This study assesses adherence and duration of therapy with FTD + TPI versus REG and explores the effect of sequencing on adherence. MA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Anuj K., Barghout, Victoria, Yenikomshian, Mihran A., Germain, Guillaume, Jacques, Philippe, Laliberté, François, Duh, Mei S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Gastrointestinal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964129/ https://www.ncbi.nlm.nih.gov/pubmed/31591140 http://dx.doi.org/10.1634/theoncologist.2019-0240

Ejemplares similares

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
por: Moriwaki, Toshikazu, et al.
Publicado: (2017)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
por: Matsumoto, Toshihiko, et al.
Publicado: (2023)

Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells
por: Matsuoka, Kazuaki, et al.
Publicado: (2018)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer
por: Patel, Manish R., et al.
Publicado: (2021)

Biomarkers of Trifluridine-Tipiracil Efficacy
por: Voutsadakis, Ioannis A.
Publicado: (2021)

Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Author Correction: Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab
por: Matsumoto, Toshihiko, et al.
Publicado: (2023)

Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer
por: Tanaka, Akira, et al.
Publicado: (2018)

Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
por: Ogata, Misato, et al.
Publicado: (2020)

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2019)

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
por: Nakajima, Hiromichi, et al.
Publicado: (2021)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
por: Signorelli, Carlo, et al.
Publicado: (2023)

Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan
por: Kagawa, Y., et al.
Publicado: (2023)

Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
por: Oki, Eiji, et al.
Publicado: (2020)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
por: Puthiamadathil, Jeevan M, et al.
Publicado: (2017)

Trifluridine/Tipiracil: Old Drug, New Tricks
por: Jeffers, Kate D.
Publicado: (2016)

Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
por: Oshima, Kotoe, et al.
Publicado: (2022)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
por: Tabernero, Josep, et al.
Publicado: (2017)

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
por: Malik, Mateusz, et al.
Publicado: (2021)

Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
por: Koper, Agnieszka, et al.
Publicado: (2023)

Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
por: Martínez-Lago, Nieves, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series
por: Voutsadakis, Ioannis A.
Publicado: (2023)

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
por: Tong, Daniel, et al.
Publicado: (2021)

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
por: Kwakman, Johannes J. M., et al.
Publicado: (2017)

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
por: Sunakawa, Yu, et al.
Publicado: (2017)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
por: Koumarianou, Anna, et al.
Publicado: (2023)

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma
por: Tella, Sri Harsha, et al.
Publicado: (2023)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
por: Takahashi, Naoki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k3leqeaf731q5ucf4juo4tjt22